# DKFZ-MOST COOPERA N IN CANCER RESEARCH – LIST OF ALL PROJECTS CA 01–CA 187 (1976-2018)

| Ca-No. | Israeli Partner | German Partner | Joint Project Title |
|---|---|---|---|
| **Project phase I – 01.01.1976 – 31.12.1979** | | | |
| 001 | E. Winocour, Weizmann Institute | G. Sauer, DKFZ | Integration of SV40 into the cellular genome |
| 002 | L. Sachs, Weizmann Institute | W. Franke, DKFZ | Membrane organisation in leukemic cells – kinetics of formation and heterogeneity of surface membrane components and mosaics and its interference with membranotropic drugs |
| 007 | E. Shaaya | E. Sekeris, DKFZ | Regulation of synthesis of HnRNA in epidermis cells of insects and its posttranscriptional modification |
| **Project phase II – 01.01.1977 – 31.12.1980** | | | |
| 003 | M. Schlesinger, Hebrew University | W. Droege, DKFZ | Analysis of lymphocyte subpopulations with a combination of physical and serological techniques |
| 004 | R. Laskov, Hebrew University | K. Eichmann, DKFZ | Control mechanisms of immunoglobulin synthesis in myeloma cells |
| 005 | F. Doljanski, Hebrew University | V. Kinzel, DKFZ | Cell surface shedding in normal and neoplastic cells |
| **Project phase III, group 1 – 01.07.1979 – 30.06.1982** | | | |
| 008 | J. Haimovich, Tel Aviv University | P. Krammer, DKFZ | Differentiation of normal and malignant T and B lymphocytes |
| 009 | S. Lavi, W. Winocour, Weizmann Institute | G. Sauer, DKFZ | Synergistic carcinogenic effects of viral and chemical agents and DNA mutagenesis in primates |
| 010 | J. Witz, Tel Aviv University | K. Munk, DKFZ | Systemic and *in situ* tumoral immunity in rats inoculated with herpes-simplex virus (HSV) transformed cells and bearing metastasising tumors |
| 011 | T. Mekori, E. Robinson, Technion | H. Kirchner, E. Storch, DKFZ | Mechanism of immunosuppression in cancer patients and experimental models. The role of adjuvant radio-chemo- and immunotherapy |
| 012 | D. Sulitzeanu, Hadassah Med. School | M. Zöller, S. Matzku, DKFZ | Identification and biological activity of antigens in immune complexes of patients with breast cancer |
| 013 | J. Treves, S. Biran, Hadassah Univ. Hospital | W. Dröge, V. Schirrmacher, DKFZ | Specific adoptive immunotherapy of human and experimental tumors by lymphocytes sensitized *in vitro* against autologous tumor cells |
| **Project phase III, group 2 – 01.10.1979 – 30.09.1982** | | | |
| 014 | E. Pick, Tel Aviv University | D. Gemsa, H. Kirchner, DKFZ | Macrophage activation induction and effects on cell cooperation |
| 015 | D. Givol, P. Lonai, Weizmann Institute | K. Eichmann, DKFZ | Expression of immunoglobin variable region determinants on functionally defined T lymphocyte populations |
| 016 | R. Ben-Ishai, Technion | H. W. Thielmann, DKFZ | A study of the mechanism of environmental carcinogenesis |
| **Projects phase III, group 3 – 01.07.1981 – 30.06.1984** | | | |
| 017 | R. Simantov, Weizmann Institute | F. Marks, DKFZ | Biochemical dissection of early promotion specific and pleiotropic effects evoked by phorbol ester tumor promoters and related compounds |
| 018 | S. Segal, E. Gorelik, Ben-Gurion University | G. Haemmerling, V. Schirrmacher, DKFZ | The immunobiology of tumor metastases |

| Ca-No. | Israeli Partner | German Partner | Joint Project Title |
|---|---|---|---|
| Project phase IV, group 1 – 01.07.1982 – 30.06.1985 | | | |
| 019 | E. Canaani, Weizmann Institute | T. Graf, DKFZ | Virus-mediated genetic rearrangements |
| 020 | M. Herzberg, Tel Aviv University | D. Werner, K. Munk, DKFZ | Nucleic acid binding activities and nucleolytic activities associated to the nuclear matrix in mammalian cells |
| 021 | J. Kapitulnik, R. Koren, Hebrew University | F. Kolar / N. Fusenig, DKFZ | Alteration of growth regulation in chemical carcinogenesis |
| Project phase IV, group 2 – 01.01.1983 – 31.12.1985 | | | |
| 022 | B. Geiger, Weizmann Institute | W. Franke, DKFZ | Biochemical and immunochemical characterization of type-specific intermediate filaments and their attachment sites in normal and in transformed cells |
| 023 | U.Z. Linttauer, I. Ginzburg, Weizmann Institute | H. Ponstingl, DKFZ | Cytostatic binding sites in normal and corresponding tumor cells |
| 024 | I. Vlodavsky, Hadassah University Hospital | V. Schirrmacher, DKFZ | Interaction of metastasizing and non-metastasizing tumors with cultured vascular endothelial cells and their underlying lamina |
| 025 | S. Shaltiel, Weizmann Institute | V. Kinzel, M. Gagelmann, DKFZ | Structure of cAMP-dependent kinases as bioregulatory enzymes |
| Project phase IV, group 3 – 01.07.1984 – 30.06.1987 | | | |
| 026 | A. Panet, Hebrew University | H. Kirchner, H. Jacobsen, DKFZ | Inhibition by interferon of herpes simplex virus or regulation of other viruses in murine cells |
| 027 | M. Bar-Eli, Ben Gurion University | G. Haemmerling, DKFZ | The molecular genetics of tumor growth |
| 028 | R. Kaempfer, Hebrew University | P. Krammer, DKFZ | Lymphokine receptors on murine B- and T-cell tumors |
| 029 | A. Raz, A. Ben-Ze'ev, Weizmann Institute | M. Zoeller, DKFZ | Escape mechanisms of metastatic tumor variants |
| Project phase V, group 1– 01.01.1986 – 31.12.1988 | | | |
| 030 | V. Rotter, Weizmann Institute | V. Schirrmacher, DKFZ | P53 expression in tumor cells of different metastatic capacity |
| 031 | S. Mitrani-Rosen-baum, Hebrew University | L. Gissmann, DKFZ | Detection and characterization of human papilloma viruses in genital lesions from Israelian patients |
| 032 | S. Lavi, Tel Aviv University | J. Schlehofer, DKFZ | The role of DNA-amplification in tumor initiation |
| 033 | Y. Milner, Hebrew University | M. Hergenhahn, DKFZ | The role of plasma membrane physical organization in control of growth and differentiation of human epidermal cells |
| 034 | J. Schlessinger, Weizmann Institute | V. Kinzel, F. Marks, DKFZ | The role of polypeptide growth factors in multistage tumorigenesis |
| 035 | H. Manor, Technion | M. Pawlita, DKFZ | Carcinogen induced replication and recombination of polyoma and lymphotropic papovavirus DNA |
| Project phase V, group 2 – 01.07.1987 – 30.06.1990 | | | |
| 036 | B. Czernobilsky, Kaplan Hospital | W. Franke, DKFZ | Intermediate filaments in germ cell tumors |
| 037 | I. Friedberg, Tel Aviv University | D. Kübler, W. Pyerin, DKFZ | Role of cell surface-mediated utilization of extracellular nucleotides in normal and transformed cells |
| 038 | Y. Kaufmann, Chaim Sheba Medical Center | W. Falk, P. Krammer, DKFZ | Induction of cytolytic lymphocytes by cytokines |

| Ca-No. | Israeli Partner | German Partner | Joint Project Title |
|---|---|---|---|
| 039 | M. Revel, Weizmann Institute | R. Zawatzky, H. Kirchner, DKFZ | Agents controlling the growth and differentiation of primitive blood lymhomyeloid/erythroid stem cells |
| Project phase V, group 3 – 01.01.1989 – 31.12.1991 | | | |
| 040 | J. Kark, Hebrew University | J. Wahrendorf, DKFZ | Biochemical predictors of 20 years cancer incidence in the Israeli Civil Servant Cohort |
| 041 | D. Wallach, Weizmann Institute | D. Maennel, DKFZ, H. Holtmann, Univ. Hannover | Mechanisms controlling the response to tumor necrosis factor |
| 042 | G. Berke, Weizmann Institute | W. Droege, DKFZ | Immunotherapy by tumor infiltration lympho-cytes (TIL) activated by IL-2: The development of large granular cytolytic T lymphocytes (LGCTL) and the function of lytic granules and perforins(s) in inducing tumor regression |
| 043 | E. Kedar, Hebrew University | V. Schirrmacher, DKFZ | Application of human cytokine and effector cells for immunotherapy of human tumors in nude mice |
| 044 | R. N. Apte, Ben Gurion University | M. Zoeller, DKFZ | Cytokine secretion of tumor cells influence on tumor initiation, progression and interaction with the immune system |
| 045 | P. Rozen, Ichilov Hospital | H. Boeing, DKFZ | Dietary factors in the recurrence and progression of colorectal adenomas; A calcium intervention study |
| Project phase VI, group 1 – 01.07.1990 – 30.06.1993 | | | |
| 046 | A. Ben-Ze'ev, Weizmann Institute | J. Kartenbeck, W. Franke, DKFZ | Regulation of synthesis of intermediate filament and desmosomal proteins in attached and unattached states of normal and transformed cells |
| 047 | Y. Shiloh, Tel Aviv University | A. Weith, M. Schwab, DKFZ | Amplification in human solid tumors: search for new oncogenes |
| 048 | J. Tal, Ben Gurion University | J. Schlehofer, DKFZ | Involvement of the NS genes in the antitumor activity of parvoviruses |
| 049 | B. Geiger, Weizmann Institute | W. Franke, DKFZ | Structure-function relationships in adhering cell junctions of normal and transformed cells |
| Project phase VI, group 2 – 01.01.1992 – 31.12.1994 | | | |
| 050 | M. Aboud, Ben Gurion University | R. Flügel, M. Löchelt, DKFZ | Tumorigenic cooperation between human retroviruses, oncogenes and other carcinogens |
| 051 | M. Oren, Weizmann Institute | M. Schwab, DKFZ | Analysis of tumor suppressor genes in human cancers |
| 052 | H. Degani, Y. Salomon, Weizmann Institute | W. Lehmann, W. E. Hull, DKFZ | Development of NMR and mass spectroscopic techniques and their application in the investigation of fatty acid and phospholipid metabolism and alterations involved in cellular transduction and malignant growth |
| 053 | S.A. Lamprecht, Ben Gurion University | G. Fürstenberger, F. Marks, DKFZ | Transforming growth factor-beta in epithelial growth control, differentiation and neoplasia |
| 054 | M. Liscovitch, Weizmann Institute | V. Kinzel, DKFZ | Role of phospholipase C and D in cell signaling and growth control |
| 055 | J. Bar-Tana, Hebrew University | D. Keppler, DKFZ | Cell signaling and growth control induced by amphipathic carboxylates – an unifying theory |
| Project phase VI, group 3 – 01.07.1993 – 30.06.1996 | | | |
| 056 | I. Ginzburg, Weizmann Institute | H. Ponstingl, DKFZ | Arrest of cell division in tumor cells by inducing expression of control proteins: (A) Cytoskeletal Tau MAP (Israel), (B) Mitotic Control Proteins (Germany) |
| 057 | G. Neufeld, Technion | R. Schwartz-Albiez, DKFZ | Growth factor regulated interaction between leukemias/lymphomas and endothelium |

| Ca-No. | Israeli Partner | German Partner | Joint Project Title |
|---|---|---|---|
| 058 | E. Keshet, Hebrew University | E. Spiess (div. W. Franke), DKFZ | Regulation of proteases and their respective inhibitors mediating cell invasiveness during angiogenesis and metastasis |
| 059 | A. Kimchi, Weizmann Institute | N. E. Fusenig, DKFZ | Negative regulating growth factors and the significance of their abrogation in carcinogenesis |
| 060 | S. Lavi, Tel Aviv University | R. Heilbronn, MPI f. Biochemie / J. Klein-schmidt, DKFZ | Onco suppression by adeno-associated viruses |
| 061 | V. Rotter, Weizmann Institute | K.H. Richter (div. F. Marks), DKFZ | The involvement of tumor suppressor p53 in differentiation |
| 062 | B. Shilo, Weizmann Institute | B. Mechler, DKFZ | Signaling pathways of *Drosophila* receptors and tumor suppressor gene products |
| Project phase VII, group 1 – 01.01.1995 – 31.12.1997 | | | |
| 063 | D. Canaani, Tel Aviv University | M. Schwab, DKFZ | Phosphorylation of proteins encoded by oncogenes and tumor suppressor genes as a determinant for protein association and tumorigenesis |
| 064 | S. Segal, Ben Gurion University | F. Momburg (div. G. Haemmerling), DKFZ | The influence of TAP peptide transporters on tumorgenisity |
| 065 | Z. Zor, Weizmann Institute | G. Fuerstenberger (div. F. Marks), DKFZ | Regulation of gene expression in tumor growth: over expression of phospholipase A2 and prostaglandin H synthase isoenzymes as potential markers for epithelial tumors |
| 066 | R. Apte, Ben Gurion University | D. Schnabel, M. Zoeller, DKFZ | Induction of immune response against T cell lymphomas by IL-1alpha and anti-CD44v monoclonal antibodies |
| 067 | G. Berke, Weizmann Institute | P. Krammer, DKFZ | Induction on tumor cell apoptosis by killer cells |
| 068 | L. Eisenbach, Weizmann Institute | M. Zoeller, DKFZ | Treatment of metastasis by activation of immune effector cells via a combination of active and passive vaccination protocols including genetic manipulation of tumor cells and lymphocytes |
| 069 | I. Witz, Tel Aviv University | V. Schirrmacher, DKFZ | Activation antigens: role in anti-tumor immune response and potential targets for therapy |
| Project phase VII, group 2 – 01.07.1996 – 30.06.1999 | | | |
| 070 | Y. Ben-Neriah, Hebrew University | W. Droege, DKFZ | Identifying signaling intermediates of the T-cell costimulatory receptor CD28 |
| 071 | Z. Fishelson, Tel Aviv University | M. Kirschfink, University of Heidelberg | Molecular basis of the resistance of tumor cells to complement-mediated lysis |
| 072 | Y. Shaul, Weizmann Institute | C. Schröder, DKFZ | Functional interaction of pX of HBV with the tumor suppressor p53 |
| 073 | L. Sherman, Sackler School of Medicine | M. Dürst (div. A. Alonso), DKFZ | Human papillomavirus (HPV) transformation: The role of HPV16 E6 in the induction of resistance to serum/Ca2+ mediated differentiation |
| 074 | Z. Eshhar, Weizmann Institute | M. Little, DKFZ | Redirecting effector lymphocytes to Hodgkin's disease/lymphoma using chimeric receptors with antibody specificity |
| 075 | Y. Groner, Weizmann Institute | M. Schwab, DKFZ | Possible role of AML2 and other genes on distal chromosome 1p for human cancers |
| 076 | A. Hochberg, Hebrew University | D. Komitowski, DKFZ | Imprinted genes in human cancer, biology, diagnosis and therapy |
| Project phase VII, group 3 – 01.01.1998 – 31.12.2000 | | | |
| 077 | N. Arber, Tel Aviv University | W. Pyerin, DKFZ | The importance of cyclin D1, RB, K-ras and cyclin-like CENP-C in cell cycle control and |

| Ca-No. | Israeli Partner | German Partner | Joint Project Title |
|---|---|---|---|
| | | | progression |
| 078 | R. Bar-Shavit, Hadassah Med. School – Hospital | P. Altevogt (div. V. Schirrmacher), DKFZ | The role of avb3 integrin and protease activated receptor in tumor metastasis: involvement of thrombin-receptor (ThR) and L1 adhesion molecule |
| 079 | A. Ben Ze'ev, Weizmann Institute | W. Franke, DKFZ | Extrajunctional function of plaque proteins in growth control, tumorigenesis and differentiation |
| 080 | E. Canaani, Weizmann Institute | R. Paro, ZMBH Heidelberg | Mechanism of action of *Drosophila* trithorax-group and polycomb-group proteins and their mammalian homologues |
| 081 | A. Ciechanover, Technion | M. Scheffner (div. E. M. de Villiers), DKFZ | Regulation of cell regulatory proteins by the ubiquitin-dependent proteolytic pathway |
| 082 | I. Friedberg, Tel Aviv University | D. Kübler (div. V. Kinzel), DKFZ | Selective growth inhibition of malignant cells by a phosphoprotein inhibitor |
| 083 | A. Levitzky, Hebrew University | F. Roesl, DKFZ | The role of EGF/IGF signal transduction in HPV 16/18-linked pathogenesis of cervical cancer |
| 084 | A. Eldor, Tel Aviv Sourasky Med. Center | K.-M. Debatin, DKFZ | Studies on the envelope glycoprotein of the avian hemangio-sarcoma retrovirus (AVH) which induces either apoptosis or proliferation in different cell types |
| Project phase VIII, group 1 – 01.07.1999 – 30.06.2002 | | | |
| 085 | A. Kimchi, Weizmann Institute | M. Schwab, DKFZ | Cell death associated proteins: Gene identification by functional approach and analysis of their apoptotic and tumor suppressor functions |
| 086 | M. Oren, Weizmann Institute | P. Krammer, DKFZ | The role of p53 in drug-induced apoptosis |
| 087 | E. Razin, Hebrew University | P. Angel, DKFZ | Identification of cellular pathways mediating cell death in response to radiation and genotoxic agents |
| 088 | G. Golomb, Hebrew University | M. Berger, DKFZ | Development and evaluation of non-viral antisense oligonucleotide and gene controlled delivery systems for the treatment of mammary carcinoma and bone osteolysis |
| 089 | E. Keshet, Hebrew University | N. E. Fusenig, DKFZ | Role of PDGF and VEGF in blood vessel formation, maturation and regression: New targets for tumor therapy |
| 090 | I. Vlodavsky, Hadassah Univ. Hospital | V. Schirrmacher, DKFZ | Novel inhibitors of tumor metastasis and angiogenesis |
| 091 | Z. Fishelson, Sackler School of Medicine | M. Kirschfink, University of Heidelberg | Sensitization of human tumor cells to complement-mediated lysis |
| Project phase VIII, group 2 – 01.01.2001 – 31.12.2003 | | | |
| 092 | O. Mandelboim, Hebrew University | F. Momburg (div. G. Haemmerling), DKFZ | Identification of NKp46 ligand: A ligand which is involved in the lysis of tumor cells and virally infected cells by natural killer cells |
| 093 | J. Bar-Tana, R. Hertz, Hebrew University | G. Schuetz, DKFZ | A biochemical and molecular genetic approach to study the role of hepatocyte nuclear factor 4 (HNF4) and suppression of tumor development by fatty acids |
| 094 | D. Ron, Technion | N. E. Fusenig, DKFZ | Modulation of the interaction of KGF with its receptor in normal and tumor cells |
| 095 | T. Tennenbaum, Bar-Ilan University | D. Breitkreutz (div. N. E. Fusenig), DKFZ | The functional relevance of alterations in integrin alpha6beta4 and protein kinase C regulation in human and mouse skin carcinogenesis |
| 096 | R. Apte, Ben Gurion University | M. Zoeller, DKFZ | Novel anti-cancer vaccines based on oral application of recombinant Salmonella typhimurium bacteria |

| Ca-No. | Israeli Partner | German Partner | Joint Project Title |
|---|---|---|---|
| 097 | V. Deutsch, A. Naparstek, Tel Aviv Med. Center | B. Fehse, A.R. Zander, Univ. Hospital Eppendorf | Expansion of human hematopoietic stem cells and megakaryocyte progenitors for transplantation in cancer patients |
| 098 | M. Liscovitch, Weizmann Institute | D. Keppler, DKFZ | Phenotypic reversal in multidrug resistant cancer cells |
| Project phase VIII, group 3 – 01.07.2002 – 30.06.2005 | | | |
| 099 | P. Fishman, Tel Aviv University | R. Koesters (div. M. v. Knebel Doeberitz), DKFZ | Targeting the adenosine A3 receptor for the treatment and prevention of colon carcinoma: molecular mechanisms and preclinical evaluation |
| 100 | G. Berke, Weizmann Institute | P. Krammer, DKFZ | The CD95 (APO-1/Fas) death system in tumor progression |
| 101 | Y. Haupt, Hebrew University | F. Roesl, DKFZ | Involvement of c-Abl in HPV-induced carcinogenesis |
| 102 | G. Neufeld, Technion | M. Mueller, DKFZ | Tyrosine kinase VEGF receptors and neuropilins and the role of their VEGF and semaphoring ligands in tumor development and progression |
| 103 | L. Sherman, Sackler School of Medicine | L. Gissmann, DKFZ | Human papillomavirus type 16 in cervical cancer: the potential role of E6 natural variants in regression of progression of viral-induced disease |
| 104 | E. Wertheimer, Tel Aviv University | D. Breitkreutz, DKFZ | Functional significance of insulin signaling in skin and skin tumorigenesis |
| 105 | S. Lavi, Tel Aviv University | P. Peschke (div. P. Huber), DKFZ | Macromolecular polymers as a novel platform for the tumor directed delivery of drugs targeting molecular processes of apoptosis and radiation |
| Phase IX, group 1 – 01.01.2004 – 31.12.2006 | | | |
| 106 | A. Fainsod, Hebrew University | C. Niehrs, DKFZ | Identification of the genetic network controlled by the caudal transcriptional regulator |
| 107 | Y. Gruenbaum, Hebrew University | H. Herrmann-Lerdon, DKFZ | The role of nuclear lamina proteins in organizing nuclear architecture in normal and transformed cells |
| 108 | D. Melamed, Technion | R. Arnold (div. P. Krammer) | Influence of antigen receptor mediated signaling in apoptosis and survival during the selection of lymphocytes |
| 109 | H. Werner, Tel Aviv University | D. Mayer, DKFZ | Functional and physical analysis of the IGF-I receptor gene in progression to advanced breast cancer |
| 110 | B. Kerem, Hebrew University | M. Schwab, DKFZ | Chromosomal fragile sites and cancer |
| 111 | M. Aboud, M. Huleihel, Ben Gurion Univ. | P. Krammer, M. Li-Weber, DKFZ | Oncogenic activity of HTLV-I Tax and its prevention |
| 112 | S. Segal, D. Fishman, Ben-Gurion Univ. | R. Ganss, G. Haemmerling, DKFZ | Tumor-associated blood vessel endothelium as a barrier to infiltration of effector immunocytes |
| 01.07.2004 – 31.12.2005 | | | |
| 113 | D. Rund, Hadasssah Univ. Hospital | A. Risch (div. of M. Bartsch), DKFZ | Genotypes of drug transporting and metabolising genes as potential modifiers of cancer risk and chemotherapy-sensitivity |
| Phase IX, group 2 – 01.07.2005 – 30.06.2008 | | | |
| 114 | G. Golomb, Hebrew University | M. Berger, DKFZ | New strategies in the treatment of osteolytic bone metastasis of mammary carcinoma |
| 115 | R. Apte, Ben-Gurion Uniersity | M. Zoeller, DKFZ | The impact of host and tumor derived IL-1 on tumor growth and host defense |
| 116 | M. Baniyash, Hebrew University | V. Umansky (div. of D. Schadendorf), | Melanoma growth, anti-tumor immune response and inflammation: a critical three-lateral |

| Ca-No. | Israeli Partner | German Partner | Joint Project Title |
|---|---|---|---|
| | | DKFZ | interrelationship for successful immunotherapy |
| 117 | Y. Ben-Neriah, Hebrew University | P. Angel, DKFZ | Molecular mechanisms driving HCC development in mouse model of hepatitis-associated cancer |
| 118 | A. Porgador, Ben-Gurion University | A. Cerwenka, DKFZ | Evaluation of function for ligands of activating natural killer cells receptors in anti-tumor immunity |
| 119 | G. Ast, Tel Aviv University | A. Hotz-Wagenblatt, S. Suhai, DKFZ | Analysis of Alu exonization and alternative splicing in cancer genes |
| 120 | Y. Shiloh, Tel Aviv University | W. Lehmann (div. of W.E. Hull), DKFZ | Identification and functional analysis of protein phosphorylation and dephosphorylation in the ATM-mediated DNA damage response |
| Phase IX, group 3 – 01.01.2007 – 31.12.2009 | | | |
| 121 | A. Eden, Hebrew University | F. Lyko, DKFZ | Hypomethylation-induced genetic instability as a factor in tumor formation |
| 122 | M. Kupiec, Tel Aviv University | I. Grummt, DKFZ | Epigenetic mechanisms regulating transcriptions and genome stability in cancer cells |
| 123 | E. Flescher, Tel Aviv University | M. Berger, DKFZ | Contribution of endoplasmic reticulum (ER) stress and mitochondrial perturbation in the death of breast and colon cancer cells induced by plant cytotoxic agents |
| 124 | A. Gross, Weizmann Institute | H. Walczak, DKFZ | The role of DNA damage-mediated BID phosphorylation for TRAIL-induced apoptosis |
| 125 | S. Lev, Weizmann Institute | I. Hoffmann, DKFZ | Identification and characterization of cytokinetic targets in cancer therapy |
| 126 | M. Neeman, Weizmann Institute | F. Kiessling (div. of W. Semmler), DKFZ | High resolution assessment of antiogenesis and normalization of tumor vessel phenotype under therapy using implanted MR-coils and functional and molecular MR-imaging methods |
| 127 | I. Vlodavsky, Cancer and Vascular Biology Res. Center | P. Beckhove (div. of V. Schirrmacher), DKFZ | Human heparanase – a promising target for the development of therapeutic strategies in cancer |
| Phase X, group 1 – 01.07.2008 – 30.06.2011 | | | |
| 128 | M. Baniyasch, Hebrew University | V. Umansky (div. of D. Schadendorf), DKFZ | Inflammation-dependent immunosuppressive tumor microenvironment: Its neutralization for successful tumor immunotherapy |
| 129 | D. Melamed, Technion | R. Arnold, P. Krammer, DKFZ | Intracellular signalling pathways controlling cell fate decisions of lymphocytes during differentiation and tumorigenesis |
| 130 | E. Pikarsky, Y. Ben-Neriah, Hebrew University | P. Angel, DKFZ | Molecular mechanisms of inflammation induced liver cancer |
| 131 | A. Kimchi, Weizmann Institute | P. Krammer, R. Arnold, DKFZ | Molecular pathways underlying apoptotic and non apoptotic cell death and their implication in cancer development |
| 132 | E. Keshet, Hebrew University | H. Augustin, DKFZ | Interplay between VEGF and angiopoietins in the vascular tumor microenvironment |
| 133 | E. Razin, Hebrew University | M. Boutros, DKFZ | Exploring the network of STAT3 and MITF in melanoma using RNAi libraries |
| 134 | A. Levitzki, Hebrew University | F. Roesl, DKFZ | The Cellular pathways leading to cancer |
| Phase X, group 2 – 01.07.2009 – 30.06.2012 | | | |
| 135 | O. Mandelboim, Hebrew University | S. Diederichs, DKFZ | Regulation and function of viral and cellular microRNAs controlling the immune response |
| 136 | N. Arber, Tel Aviv Sourasky Medical Center | P. Altevogt, DKFZ | Monochlonal antibodies targeting CD24 in the treatment of pancreatic cancer |

| Ca-No. | Israeli Partner | German Partner | Joint Project Title |
|---|---|---|---|
| 137 | Y. Shaul, Weizmann Institute | T. Hofmann, DKFZ | Regulation of p53 family tumor suppressors under DNA damage stress |
| 138 | G. Neufeld, Technion | A. Fischer, DKFZ | The complex interactions of semaphorins and the delta-notch pathway in tumor angiogenesis |
| 139 | G. Ast, Tel Aviv University | A. Hotz-Wagenblatt, DKFZ | Defining control and function of alternative splicing during tumorigenesis |
| Phase X, group 3 – 01.07.2010 – 30.06.2013 | | | |
| 140 | M. Fainzilber, Weizmann Institute | N. Brady, DKFZ | RTK-dependent cell death in pediatric tumors of neural origin |
| 141 | S. Izraeli, Sheba Medical Center | A. Kraemer, DKFZ | The roles of SIL(STIL) in centrosome biology – relevance to cancer and developmental disorders |
| 142 | A. Porgador, Ben-Gurion University | A. Cerwenka, DKFZ | Characterization and regulation of NCR and NKG2D ligands in cancer |
| 143 | R. Apte, Ben-Gurion University | M. Mueller, DKFZ | Interactions between cancer associated fibroblasts (CAFs) and myeloid-derived inflammatory cells in the dynamic phenotype of the microenvironment during tumor progression; basic mechanisms and preclinical applications of novel intervention strategies |
| 144 | I. Vlodavsky, Technion | P. Beckhove, DKFZ | Heparanase: a promising target and tumor antigen for therapeutic strategies in cancer |
| Phase XI, group 1 – 01.07.2011 – 30.06.2014 | | | |
| 145 | M. Kupiec, Tel Aviv Univ. | R. Eils, R. Koenig, DKFZ | A systems-level dissection of Telomere biology |
| 146 | E. Meshorer, Hebrew University | K. Rippe, DKFZ | Identifying features of chromatin organization and epigenetic modifications associated with pluripotency and self-renewal in stem cells and tumor initiating cells |
| 147 | E. Pikarsky, Hebrew University | P. Angel, DKFZ | Cross species inflammatory oncogenomics to identify therapeutic targets for liver cancer |
| 148 | G. Shakar, T. Feferman, Weizmann Institute | G. Haemmerling, DKFZ | Control of CTL-mediated tumor rejection by regulatory T cells: Imaging and molecular mechanisms |
| 149 | Y. Ben-Neriah, Hebrew University | H. Allgayer, DKFZ | microRNA control of tissue invasion and intestinal cancer |
| Phase XI, group 2 – 01.07.2012 – 30.06.2015 | | | |
| 150 | Y. Bergman, Hebrew University | F. Lyko, DKFZ | The DNA methylation program in inflammation cancer |
| 151 | J. Abramson, Weizmann Institute | M. Feuerer, DKFZ | Modulation of regulatory T cell function by novel $T_{reg}$-specific monoclonal antibodies |
| 152 | N. Erez, Tel Aviv University | K. Mueller-Decker, DKFZ | Characterizing the role of the microenvironment in facilitating melanoma brain metastasis |
| 153 | A. Ben-Baruch, Tel Aviv University | S. Wiemann, DKFZ | microRNA control of MSC and CAF in breast cancer: A proangiogenic switch and cell-remodeling |
| 154 | V. Krizhanovsky, Weizmann Institute | J. Hess, DKFZ | Impact of the pro-inflammatory microenvironment on cellular programs of oncogene induced senescence during carcinogenesis |
| Phase XI, group 3 – 01.07.2013 – 30.06.2016 | | | |
| 155 | B. Kerem, Hebrew University | F. Roesl, DKFZ | Folate deficiency and human papilloma virus-induced carcinogenesis |
| 156 | D. Sprinzak, Tel Aviv University | A. Fischer, DKFZ | Quantitative analysis of Delta-Notch membrane distributions and its regulation during angiogenesis and metastasis |
| 157 | N. Karin, | V. Umansky, DKFZ | The role of CCR5 in the recruitment of myeloid- |

| Ca-No. | Israeli Partner | German Partner | Joint Project Title |
|---|---|---|---|
| | Technion | | derived suppressor cells (MDSC) from the bone marrow to support melanoma progression |
| 158 | R. Seger, Weizmann Institute | E. Burgermeister, University of Heidelberg, Sponsor: H. Augustin | Function of the lipid phospatase MTMR7 in anti-EGFR therapy resistance of colorectal cancer (CRC) |
| 159 | C. Levy, Tel Aviv University | J. Hoheisel, DKFZ | Exploring microRNA transfer and melanoma progression: novel concept of cell-cell communication in the tumor microenvironment |
| Phase XII, group 1 – 01.07.2014 – 30.06.2017 | | | |
| 160 | R. Beck-Barkai, Tel Aviv University; B. Geiger, Weizmann Institute | E. Gladilin, DKFZ | Dissecting the contribution of vimentin intermediate filaments to mechanical and structural properties of cancer cells, using advanced physical approaches |
| 161 | I. Ben-Porath, Hebrew University | T. Hofmann, DKFZ | Molecular regulation of cellular fate by p53: the choice between apoptosis and senescence |
| 162 | M. Berger, Hebrew University | A. Kraemer, DKFZ | The role of the quiescence inducer Slfn2, in T-ALL development |
| 163 | E.Galun, Hadassah Med. Organization | L. Zender, DKFZ | Tumor suppressive mechanisms of micro RNA 122* |
| 164 | M. Lotem, Hadassah Med. Organization | P. Beckhove, DKFZ | Identification of anticancer immune checkpoint molecules expressed by tumor cells or lymphocytes using high-throughput RNAi screening |
| 2495 | N. Papo, Ben-Gurion Univ. | A. Miller, DKFZ | Developing dual PAR1/KLK6 inhibitors based on bi-specific APPI peptide-small molecule conjugates for clinical translation as therapeutic anticancer agents |
| 2511 | A. Smadar, Schneider Children's Medical Center | H. Witt, DKFZ | Unraveling driver mutations and epigenetic alterations in pediatric solid tumors |
| Phase XII, group 2 – 01.07.2015 – 30.06.2018 | | | |
| 2526 | A.Admon, Technion | M. Platten, DKFZ | Exploiting the immunopeptidome of experimental glioma |
| 165 | D. Friedmann-Morvinski, Tel Aviv Univ. | J. Gronych, D. Jones, DKFZ | Understanding the functional impact of genetic alterations in brain tumors |
| 166 | I. Shachar, Weizmann Institute | M. Seiffert, DKFZ | Functional characterization of pathogenic changes in the microenvironment of chronic lymphocytic leukemia, with a focus on immunomodulatory SLAM receptors |
| 167 | L. Gilboa, Weizmann Institute | M. Boutros, DKFZ | A comprehensive functional analysis of niche-stem cell interactions |
| 168 | T. Lapidot, Weizmann Institute | H. Augustin, DKFZ | Regulation of normal and leukemic human stem cells by the endothelial blood-bone marrow barrier |
| 169 | D. Ginsberg, Bar-Ilan University | I. Grummt, DKFZ | A novel mode of non-coding RNA in gene regulation: An E2F1-dependent antisense RNA activates expression of the proto-oncogene *SPHK* |
| Phase XII, group 3 – 01.07.2016 – 30.06.2019 | | | |
| 170 | E. Pikarsky, Hebrew University | M. Heikenwälder, DKFZ | Mechanisms supporting hepatic ectopic lymphoid-like structures (ELS) development and egression of ELS-resident tumor progenitors |
| 171 | B. Rotblat, Ben-Gurion University | M. Remke, DKFZ, DKTK Univ. Hospital Düsseldorf | Delinaeting the role of the long noncoding RNA TP73-AS1 in medulloblastoma |

| Ca-No. | Israeli Partner | German Partner | Joint Project Title |
|---|---|---|---|
| 172 | A. Porgador, Ben-Gurion University | A. Cerwenka, DKFZ | Potentiating immunotherapy of cancer by harnessing natural killer cell receptors |
| 173 | T. Shlomi, Technion | J. Hoheisel, DKFZ | An integrated experimental-computational study of metabolic adaptions underlying antifolate resistance in cancer and their targeting via synthetic lethality |
| 174 | N. Friedman, Weizmann Institute | T. Höfer, DKFZ | Studying T cell diversification using single cell experiments and mathematical modelling – towards rational design of anti-tumor T cell responses |
| 175 | G. Ast, Tel Aviv University | A. Hotz-Wagenblatt, M. Kool, DKFZ | Analysis of regulatory pathways leading alternative splicing aberrations in CNS ependymoma and breast cancer |
| Phase XIII, group 1 – 01.07.2017 – 30.06.2020 | | | |
| 176 | M. Oren, Weizmann Institute | J. Krijgsveld, DKFZ | Dynamic changes in the chromatin-bound p53 interactome in normal and cancer cells |
| 177 | Y. Bugamin, Hebrew University | P. Lichter, A. Ernst, DKFZ | lnvestigation of the permissiveness to chromothripsis in the context of the lineage, the differentiation status and the mitotic state of cells with compromised p53 or ATM function |
| 178 | E. Keshet, Hebrew University | A. Fischer, DKFZ | Reciprocal tumor -blood vessels communication impacting on cancer progression and metastasis. |
| 179 | R. Gazit, Ben Gurion University | M. Milsom, DKFZ | Cancerous impact of chronic stress-hematopoiesis |
| 180 | E. Meshorer, Hebrew University | K. Rippe, DKFZ | Deciphering the 'histone code' and tumor suppressor functions of the ATRX chromatin network |
| 181 | Z. Fridlender, Hadassah Medical Center | V. Umansky, DKFZ | The role of neutrophils and myeloid-derived suppressor cells (MDSC) in metastatic cancer lesions and their effect on existing immunotherapies |
| Phase XIII, group 2 – 01.07.2018 – 30.06.2021 | | | |
| 182 | Jacob Rachmilewitz, Hadasssah Medical Center | Frank Rösl, DKFZ | Macrophage-assisted DNA repair in the context of cutaneous papillomavirus/UV-induced skin carcinogenesis |
| 183 | Rina Rosenzweig, Weizmann Institute | Bernd Bukau, DKFZ | Working principles of the Hsp70 chaperone system in cancer biology |
| 184 | Eran Bacharach, Tel Aviv University | Antonio Marchini, DKFZ | Enhancing the efficacy of oncolytic viruses against prostate cancer through combination therapy |
| 185 | Shai Izraeli, Sheba Medical Center | Stefan Fröhling and Stefan Gröschel, DKFZ | Synthetic lethal targeting of acute myeloid leukemia driven by GATA2 haploinsufficiency |
| 186 | Ofer Mandelboim, Hebrew University- | Nina Papavasiliou, DKFZ | ADAR1 involvement in NK activity against cancer |
| 187 | Adit Ben-Baruch, Tel Aviv University- | Stefan Wiemann and Cindy Körner, DKFZ | Tumor microenvironment-driven reprogramming of luminal-A tumors towards a metastatic phenotype: Molecular determinants, epigenetic plasticity and clinical implications |